NZ724133A - Tfpi inhibitors and methods of use - Google Patents

Tfpi inhibitors and methods of use

Info

Publication number
NZ724133A
NZ724133A NZ724133A NZ72413313A NZ724133A NZ 724133 A NZ724133 A NZ 724133A NZ 724133 A NZ724133 A NZ 724133A NZ 72413313 A NZ72413313 A NZ 72413313A NZ 724133 A NZ724133 A NZ 724133A
Authority
NZ
New Zealand
Prior art keywords
methods
tfpi
peptide
tfpi inhibitors
inhibitors
Prior art date
Application number
NZ724133A
Inventor
Michael Dockal
Friedrich Scheiflinger
Rudolf Hartmann
Frank Osterkamp
Thomas Polakowski
Ulrich Reineke
Original Assignee
Baxalta Inc
Baxalta GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxalta Inc, Baxalta GmbH filed Critical Baxalta Inc
Priority to NZ749998A priority Critical patent/NZ749998A/en
Publication of NZ724133A publication Critical patent/NZ724133A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8114—Kunitz type inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/81—Protease inhibitors
    • G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • G01N2333/811—Serine protease (E.C. 3.4.21) inhibitors
    • G01N2333/8114—Kunitz type inhibitors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/20—Screening for compounds of potential therapeutic value cell-free systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A peptide complex comprising a first peptide and a second peptide, wherein the peptide complex comprises 30-60 amino acids and binds to at least two different TFPI epitopes and inhibits two or more TFPI functions.
NZ724133A 2012-03-21 2013-01-31 Tfpi inhibitors and methods of use NZ724133A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NZ749998A NZ749998A (en) 2012-03-21 2013-01-31 Tfpi inhibitors and methods of use

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261613865P 2012-03-21 2012-03-21
NZ629130A NZ629130A (en) 2012-03-21 2013-01-31 Tfpi inhibitors and methods of use

Publications (1)

Publication Number Publication Date
NZ724133A true NZ724133A (en) 2020-07-31

Family

ID=47682077

Family Applications (3)

Application Number Title Priority Date Filing Date
NZ749998A NZ749998A (en) 2012-03-21 2013-01-31 Tfpi inhibitors and methods of use
NZ724133A NZ724133A (en) 2012-03-21 2013-01-31 Tfpi inhibitors and methods of use
NZ629130A NZ629130A (en) 2012-03-21 2013-01-31 Tfpi inhibitors and methods of use

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NZ749998A NZ749998A (en) 2012-03-21 2013-01-31 Tfpi inhibitors and methods of use

Family Applications After (1)

Application Number Title Priority Date Filing Date
NZ629130A NZ629130A (en) 2012-03-21 2013-01-31 Tfpi inhibitors and methods of use

Country Status (17)

Country Link
US (3) US8962563B2 (en)
EP (1) EP2827883B1 (en)
JP (2) JP2015514070A (en)
KR (2) KR20140143191A (en)
CN (3) CN104302306B (en)
AU (2) AU2013235741C1 (en)
BR (1) BR112014022435B1 (en)
CA (1) CA2867363C (en)
DK (1) DK2827883T3 (en)
ES (1) ES2733958T3 (en)
HK (1) HK1206282A1 (en)
HR (1) HRP20191160T1 (en)
HU (1) HUE046572T2 (en)
LT (1) LT2827883T (en)
NZ (3) NZ749998A (en)
SI (1) SI2827883T1 (en)
WO (1) WO2013141965A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9580758B2 (en) 2013-11-12 2017-02-28 Luc Montagnier System and method for the detection and treatment of infection by a microbial agent associated with HIV infection
CN106232615B (en) 2014-02-28 2021-06-01 3B制药有限公司 Peptides and methods of use thereof
JP6783754B2 (en) 2014-09-17 2020-11-11 ノヴォ ノルディスク アー／エス Antibodies capable of binding two epitopes on tissue factor pathway inhibitors (1-161)
ES2959277T3 (en) * 2016-05-13 2024-02-22 Scripps Research Inst Compositions and methods for antithrombotic and hemostatic therapies
CA3145872A1 (en) * 2019-07-08 2021-01-14 3B Pharmaceuticals Gmbh Compounds comprising a fibroblast activation protein ligand and use thereof
CA3171988A1 (en) * 2020-02-22 2021-08-26 Jcr Pharmaceuticals Co., Ltd. Human transferrin receptor binding peptide
WO2023170680A1 (en) 2022-03-08 2023-09-14 Equashield Medical Ltd Fluid transfer station in a robotic pharmaceutical preparation system

Family Cites Families (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (en) 1979-07-11 1985-06-05 味の素株式会社 blood substitute
JPS5733175A (en) 1980-07-31 1982-02-23 Mitsubishi Electric Corp Transmitter for signal of elevator
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
JPS607193A (en) 1983-06-25 1985-01-14 古河電気工業株式会社 Soldering furnace for circuit board
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
DE3675588D1 (en) 1985-06-19 1990-12-20 Ajinomoto Kk HAEMOGLOBIN TIED TO A POLY (ALKENYLENE OXIDE).
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4966852A (en) 1987-07-23 1990-10-30 Monsanto Company DNA clone of human tissue factor inhibitor
IL87171A (en) 1987-11-23 1995-08-31 Monsanto Co cDNA of human tissue factor inhibitor
US5663143A (en) 1988-09-02 1997-09-02 Dyax Corp. Engineered human-derived kunitz domains that inhibit human neutrophil elastase
US5219994A (en) 1988-11-08 1993-06-15 W. Alton Jones Cell Science Center, Inc. Inhibitor of tissue factor activity
US5466468A (en) 1990-04-03 1995-11-14 Ciba-Geigy Corporation Parenterally administrable liposome formulation comprising synthetic lipids
DK146190D0 (en) 1990-06-15 1990-06-15 Novo Nordisk As HIS UNKNOWN RELATIONSHIPS
US5622988A (en) 1990-06-15 1997-04-22 Novo Nordisk A/S Use of a low molecular weight metabolite from fungus for reducing prolonged coagulation time
US5849703A (en) 1990-08-27 1998-12-15 G. D. Searle & Co. Pre-formed anticoagulant heparin/TFPI complexes
DK261490D0 (en) 1990-10-31 1990-10-31 Novo Nordisk As NEW PHARMACEUTICAL COMPOUND
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
JPH04252954A (en) 1991-01-29 1992-09-08 Asahi Chem Ind Co Ltd Measuring method, reagent and kit for protein
US5833982A (en) 1991-02-28 1998-11-10 Zymogenetics, Inc. Modified factor VII
US5997864A (en) 1995-06-07 1999-12-07 Novo Nordisk A/S Modified factor VII
JPH067193A (en) 1991-11-29 1994-01-18 Teijin Ltd Monoclonal antibody
EP0539975A1 (en) 1991-10-31 1993-05-05 Teijin Limited Method for immunological assay of free lipoprotein-associated coagulation inhibitor (LACI) and kit therefor
IL104324A0 (en) 1992-01-07 1993-05-13 Novo Nordisk As Variant of human kunitz-type protease inhibitor
IL104326A0 (en) 1992-01-07 1993-05-13 Novo Nordisk As Variant of human kunitz-type protease inhibitor
IL104314A0 (en) 1992-01-07 1993-05-13 Novo Nordisk As Human kunitz-type protease inhibitor and variants thereof,their production and pharmaceutical compositions containing them
IL104327A0 (en) 1992-01-07 1993-05-13 Novo Nordisk As Variant of human kunitz-type protease inhibitor
IL104325A (en) 1992-01-07 2000-10-31 Novo Nordisk As Variants of human kunitz-type protease inhibitor domain II of tissue factor pathway inhibitor (TFPI) pharmaceutical compositions containing them a DNA construct encoding them their expression vectors a cell containing said DNA constructs and methods for the production of all the above
AU4784693A (en) 1992-07-24 1994-02-14 Oklahoma Medical Research Foundation Blockade of protein c activation reduces microvascular surgical blood loss
JPH06153985A (en) 1992-11-16 1994-06-03 Teijin Ltd Monoclonal antibody
US5439686A (en) 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
ES2219646T5 (en) 1993-02-22 2008-11-01 Abraxis Bioscience, Inc. METHODS FOR THE IN VIVO ADMINISTRATION OF BIOLOGICAL COMPOUNDS AND USEFUL COMPOSITIONS FOR THE SAME.
CA2170030A1 (en) 1993-09-14 1995-03-23 Robert A. Lazarus Pharmaceutical compositions containing ecotin and homologs thereof
US5455338A (en) 1993-11-05 1995-10-03 Zymogenetics, Inc. DNA encoding novel human kunitz-type inhibitors and methods relating thereto
ES2229236T3 (en) 1994-01-11 2005-04-16 Dyax Corporation INHIBITORS OF THE HUMAN PLASMINE DERIVED FROM THE DOMAINS OF KUNITZ.
US5902582A (en) 1995-09-05 1999-05-11 Chiron Corporation Use of TFPI inhibitor for treatment of cancer
JP3681206B2 (en) 1995-12-26 2005-08-10 株式会社三菱化学ヤトロン Anti-factor Xa / tissue factor pathway inhibitor complex monoclonal antibody and use thereof
US6262233B1 (en) 1997-01-31 2001-07-17 Human Genome Sciences, Inc. Tissue factor pathway inhibitor-3
US20050032690A1 (en) 1997-09-10 2005-02-10 Rojkjaer Lisa Payne Factor VII polypeptides for preventing formation of inhibitors in subjects with haemophilia
JP2002503701A (en) 1998-02-18 2002-02-05 ハーバー−ユーシーエルエイ リサーチ アンド エデュケーション インスティテュート Antimicrobial peptides and derived metapeptides
JP2000128803A (en) 1998-10-19 2000-05-09 Shionogi & Co Ltd Tissue factor pass way inhibitor-2 antibody
JP2003505678A (en) 1999-07-23 2003-02-12 ザ スクリップス リサーチ インスティテュート Method for measuring coagulation factor activity in whole blood
US6180607B1 (en) 1999-08-05 2001-01-30 Christopher Davies Protein having proteinase inhibitor activity
US6458387B1 (en) 1999-10-18 2002-10-01 Epic Therapeutics, Inc. Sustained release microspheres
AU2236201A (en) 1999-11-16 2001-05-30 Academisch Ziekenhuis Leiden Compositions and methods for regulating tumor-associated antigen expression
US6821775B1 (en) 2000-02-11 2004-11-23 Genvec, Inc. Viral vector encoding pigment epithelium-derived factor
US7015194B2 (en) 2000-05-10 2006-03-21 Novo Nordisk A/S Pharmaceutical composition comprising factor VIIa and anti-TFPI
CN1304049C (en) 2000-05-10 2007-03-14 诺沃挪第克健康护理股份公司 Pharmaceutical composition comprising factor VIIa and factor XIII
DE60133271T2 (en) 2000-05-16 2009-04-23 Genentech, Inc., South San Francisco TREATMENT OF CORDIAL DISEASES
AU2002230390A1 (en) 2000-10-05 2002-04-29 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Ixodes scapularis tissue factor pathway inhibitor
EP1335661B1 (en) 2000-10-27 2009-05-06 Baxter Healthcare S.A. Production of microspheres
US20030040480A1 (en) 2001-07-20 2003-02-27 Rasmus Rojkjaer Pharmaceutical composition comprising factor VII polypeptides and factor XI polypeptides
AU2002354846B2 (en) 2001-07-20 2007-08-02 Novo Nordisk Health Care Ag Pharmaceutical composition comprising factor VII polypeptides and factor XI polypeptides
US20080026068A1 (en) 2001-08-16 2008-01-31 Baxter Healthcare S.A. Pulmonary delivery of spherical insulin microparticles
US20050233945A1 (en) 2003-07-18 2005-10-20 Larry Brown Methods for fabrication, uses and compositions of small spherical particles of insulin prepared by controlled phase separation
WO2003015750A1 (en) 2001-08-16 2003-02-27 Baxter International, Inc. Propellant-based microparticle formulations
US20030129193A1 (en) 2001-09-27 2003-07-10 Board Of Regents, The University Of Texas System And Peregrine Pharmaceuticals, Inc. Combined methods for tumor vasculature coaguligand treatment
CN1176943C (en) * 2001-10-08 2004-11-24 复旦大学 Novel recombinant human tissue factor pathway inhibitor active peptide and its preparation method
US7291587B2 (en) 2001-11-09 2007-11-06 Novo Nordisk Healthcare A/G Pharmaceutical composition comprising factor VII polypeptides and TAFI polypeptides
WO2003039579A1 (en) 2001-11-09 2003-05-15 Novo Nordisk Health Care Ag Pharmaceutical composition comprising factor vii polypeptides and tafi polypeptides
US20050214836A1 (en) 2002-08-30 2005-09-29 Oncotherapy Science, Inc. Method of diagnosing ovarian endometriosis
US8809504B2 (en) 2002-09-03 2014-08-19 Vit Lauermann Inhibitor which is deactivatable by a reagent produced by a target cell
EP1403638A1 (en) 2002-09-25 2004-03-31 Mondobiotech SA Molecular methods for diagnosing interstitial lung diseases
ES2362424T3 (en) 2003-01-07 2011-07-05 Dyax Corporation KUNITZ DOMAIN LIBRARY.
AU2003229678A1 (en) 2003-04-15 2004-11-04 Dirk Koczan Method for diagnosing rheumatoid arthritis or osteoarthritis
US20050142205A1 (en) 2003-07-18 2005-06-30 Julia Rashba-Step Methods for encapsulating small spherical particles prepared by controlled phase separation
US20070092452A1 (en) 2003-07-18 2007-04-26 Julia Rashba-Step Methods for fabrication, uses, compositions of inhalable spherical particles
JP2007508240A (en) 2003-07-22 2007-04-05 バクスター・インターナショナル・インコーポレイテッド Small spherical particles of low molecular weight organic molecules and methods for their preparation and use
WO2005024006A2 (en) 2003-09-09 2005-03-17 Novo Nordisk Health Care Ag Coagulation factor vii polypeptides
CN1863908B (en) 2003-09-09 2010-08-04 诺和诺德医疗保健公司 Coagulation factor vii polypeptides
EP1668371B1 (en) 2003-09-24 2012-05-09 Oncotherapy Science, Inc. Method of diagnosing ovarian endometriosis using tfpi-2 protein
PL1667743T3 (en) 2003-09-29 2008-06-30 Hemoteq Ag Biocompatible, biostable coating of medical surfaces
US20090232866A1 (en) 2003-10-07 2009-09-17 Mariann Pavone-Gyongyosi Oligopeptides as coating material for medical products
EP1692313A2 (en) 2003-11-20 2006-08-23 Sanofi Pasteur Inc. Methods for purifying pertussis toxin and peptides useful therefor
BRPI0416461A (en) 2003-11-20 2007-03-06 Novo Nordisk Healthcare Ag method for treating bleeding episodes, pharmaceutical formulation, and use of a fxi polypeptide
US20050181978A1 (en) 2003-11-20 2005-08-18 Rasmus Rojkjaer Therapeutic use of factor XI
US20050147689A1 (en) 2003-12-30 2005-07-07 Egilmez Nejat K. Method for inhibiting the growth of gastrointestinal tract tumors
EA012370B1 (en) 2004-02-28 2009-10-30 Хемотек Аг Stent with biocompatible coating and methods for producing thereof
WO2005107795A1 (en) 2004-05-11 2005-11-17 Novo Nordisk Health Care Ag Use of factor viia for the treatment of burn traumas
EP1753404A1 (en) 2004-05-12 2007-02-21 Baxter International Inc. Microspheres comprising protein and showing injectability at high concentrations of said agent
US8728525B2 (en) 2004-05-12 2014-05-20 Baxter International Inc. Protein microspheres retaining pharmacokinetic and pharmacodynamic properties
WO2005115442A1 (en) 2004-05-25 2005-12-08 Novo Nordisk Health Care Ag Use of coagulation factor xiii for treatment of post surgical bleedings
ES2482105T3 (en) 2004-05-27 2014-08-01 Baxter International Inc. Procedures for treating bleeding disorders using sulfated polysaccharides
EP1761630A2 (en) 2004-06-21 2007-03-14 Novo Nordisk Health Care AG Glycosylation-disrupted factor vii variants
US20090004175A1 (en) 2004-07-16 2009-01-01 Novo Nordick Health Care A/G Methods for Optimizing Forming Vlla-Based Hemostatic Treatment
US20060040896A1 (en) 2004-08-18 2006-02-23 Paringenix, Inc. Method and medicament for anticoagulation using a sulfated polysaccharide with enhanced anti-inflammatory activity
JP4252954B2 (en) 2004-12-02 2009-04-08 インターナショナル・ビジネス・マシーンズ・コーポレーション Information processing apparatus, power management method for information processing apparatus, and program therefor
US20090130086A1 (en) 2005-02-28 2009-05-21 Novo Nordisk Health Care Ag FXIII Variants with Improved Properties
WO2006096345A2 (en) 2005-03-04 2006-09-14 The Board Of Trustees Of The University Of Illinois Coagulation and fibrinolytic cascades modulator
CN101188996B (en) 2005-04-27 2013-03-27 巴克斯特国际公司 Surface-modified microparticles and methods of forming and using the same
KR20080008364A (en) 2005-05-05 2008-01-23 헤모텍 아게 All-over coating of vessel stents
WO2006128497A1 (en) 2005-06-01 2006-12-07 Novo Nordisk A/S Pharmaceutical formulation of factor xi
US20080161425A1 (en) 2005-07-29 2008-07-03 Universiteit Van Maastricht Regulation of Tissue Factor Activity by Protein S and Tissue Factor Pathway Inhibitor
DE102005039579B4 (en) 2005-08-19 2022-06-30 Magforce Ag Method for introducing therapeutic substances into cells
GB0525999D0 (en) 2005-12-21 2006-02-01 Ares Trading Sa Novel members of the kazal family of serine protease inhibitors
PL3150236T3 (en) 2006-02-09 2019-06-28 B. Braun Melsungen Ag Coating method for a folded balloon
US20070192033A1 (en) 2006-02-16 2007-08-16 Microsoft Corporation Molecular interaction predictors
WO2007127841A2 (en) 2006-04-26 2007-11-08 Arteriocyte Medical Systems, Inc. Compositions and methods of preparation thereof
US20070281031A1 (en) 2006-06-01 2007-12-06 Guohan Yang Microparticles and methods for production thereof
EP1892303A1 (en) 2006-08-22 2008-02-27 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Methods for identifying therapeutical targets in tumors and for determining and targeting angiogenesis and hemostasis related to adenocarcinomas of the lung
EP1895436A1 (en) 2006-08-31 2008-03-05 Silicos NV Method for evolving molecules and computer program for implementing the same
EP1913962A1 (en) 2006-10-22 2008-04-23 Ophir Perelson Expandable medical device for the treatment and prevention of cardiovascular diseases
EP2121767B1 (en) 2007-02-23 2014-04-09 Baxter International Inc. Process methods for fucoidan purification from seaweed extracts
EP1972687A1 (en) 2007-03-23 2008-09-24 GenOdyssee Polynucleotides and polypeptides of human factor VII gene, SNPs
US20100137211A1 (en) 2007-04-11 2010-06-03 Monahan Paul E Methods and compositions for intra-articular coagulation proteins
EP2915564B1 (en) 2007-09-28 2020-11-04 Portola Pharmaceuticals, Inc. Antidotes for factor XA inhibitors and methods of using the same
US20100297257A1 (en) 2007-11-09 2010-11-25 National Institutes Of Health (Nih), U.S. Dept. Of Health And Human Services (Dhhs) Anticoagulant antagonist and hemophillia procoagulant
WO2009080054A1 (en) 2007-12-21 2009-07-02 Ifxa A/S Protease inhibitor
FR2934052B1 (en) 2008-07-17 2011-11-25 Stago Diagnostica ASSAY OF THE ACTIVITY OF CIRCULATING TISSUE FACTOR
UA112050C2 (en) 2008-08-04 2016-07-25 БАЄР ХЕЛСКЕР ЛЛСі THERAPEUTIC COMPOSITION CONTAINING MONOCLONAL ANTIBODY AGAINST TISSUE FACTOR INHIBITOR (TFPI)
KR20110039348A (en) 2008-08-06 2011-04-15 노보 노르디스크 헬스 케어 악티엔게젤샤프트 Conjugated proteins with prolonged in vivo efficacy
KR100994996B1 (en) 2008-08-06 2010-11-18 한국과학기술연구원 Biomarkers for identification of exposure to phenanthrene and the method of identification using the same
KR101977846B1 (en) * 2008-12-19 2019-05-14 박스알타 인코퍼레이티드 Tfpi inhibitors and methods of use
JP5730983B2 (en) 2010-03-19 2015-06-10 バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ TFPI inhibitors and methods of use
BR112012028704A2 (en) 2010-05-13 2019-09-24 Univ Indiana Res & Tech Corp a peptide superfamily glugagon compound displaying receptor activity with nuclear hormone, prodrug, dimer or multimer, pharmaceutical composition comprising it and method of administration thereof.
PT2694544T (en) * 2011-04-01 2019-04-02 Bayer Healthcare Llc Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
US20140329669A1 (en) 2012-01-23 2014-11-06 N.E. Chemcat Corporation Alumina material containing barium sulfate and exhaust gas purifying catalyst using same
JP6153985B2 (en) 2015-10-16 2017-06-28 株式会社スクウェア・エニックス Video game processing program, video game processing system, and video game processing method

Also Published As

Publication number Publication date
AU2017221855A1 (en) 2017-09-21
CN109134614A (en) 2019-01-04
AU2017221855B2 (en) 2019-08-22
US20130252896A1 (en) 2013-09-26
CA2867363C (en) 2023-02-28
US9873720B2 (en) 2018-01-23
AU2013235741B2 (en) 2017-06-15
CN104302306A (en) 2015-01-21
BR112014022435A2 (en) 2017-07-11
KR20200014448A (en) 2020-02-10
US20170174727A1 (en) 2017-06-22
HK1206282A1 (en) 2016-01-08
CN104302306B (en) 2019-03-22
EP2827883A1 (en) 2015-01-28
KR20140143191A (en) 2014-12-15
AU2013235741C1 (en) 2017-12-21
ES2733958T3 (en) 2019-12-03
SI2827883T1 (en) 2019-08-30
KR102263685B1 (en) 2021-06-11
EP2827883B1 (en) 2019-05-08
US8962563B2 (en) 2015-02-24
NZ629130A (en) 2016-10-28
US10800816B2 (en) 2020-10-13
CA2867363A1 (en) 2013-09-26
WO2013141965A1 (en) 2013-09-26
CN109111505A (en) 2019-01-01
JP2019108360A (en) 2019-07-04
LT2827883T (en) 2019-08-12
DK2827883T3 (en) 2019-07-29
JP7303640B2 (en) 2023-07-05
HRP20191160T1 (en) 2019-10-04
BR112014022435B1 (en) 2023-02-14
JP2015514070A (en) 2015-05-18
US20180155399A1 (en) 2018-06-07
AU2013235741A1 (en) 2014-09-18
HUE046572T2 (en) 2020-03-30
NZ749998A (en) 2023-06-30

Similar Documents

Publication Publication Date Title
NZ629130A (en) Tfpi inhibitors and methods of use
MX2019011952A (en) Anti-garp protein and uses thereof.
MX2015011075A (en) Therapeutic peptides.
DK2728002T3 (en) HETERODIMERIZED POLYPEPTIDE
EA201390084A1 (en) SYSTEMS AND METHODS OF CREATING A SURFACE IN SPACE FAULT
EP2981543A4 (en) Novel 4 7 peptide antagonists
EP3082805A4 (en) Substituted amino triazoles, and methods using same
EP3040344A4 (en) Fab REGION-BINDING PEPTIDE
MX355128B (en) Peptide inhibitors of bace1.
MX2016004802A (en) Anti-rsp02 and/or anti-rsp03 antibodies and their uses.
EP3087093A4 (en) Pharmaceutically relevant aromatic-cationic peptides
EP3013789A4 (en) Amino acid and peptide conjugates and conjugation process
EP3022220A4 (en) Protease-resistant peptide ligands
EP3020724A4 (en) Cell-penetrating peptide and conjugate comprising same
EP2822654A4 (en) Orally active, cell-penetrating homing peptide and methods of using same
MY180179A (en) A novel modified ornithine decarboxylase protein and a use thereof
EP3322444A4 (en) A therapeutic agent for a tumor comprising an ido inhibitor administered in combination with an antibody
EP2999712A4 (en) Antifungal plant proteins, peptides, and methods of use
MX2015010023A (en) Anti-cd83 antibodies and use thereof.
IN2014DN09585A (en)
EP3263584A4 (en) Peptide for targeting autophagic cells and use thereof
NZ717192A (en) Anti-inflammatory tripeptides
EP3004134A4 (en) Peptide ligation
PT2899198T (en) Synthetic pntx(19) peptide, pharmaceutical compositions and use
FR3000169B1 (en) VALVE, IN PARTICULAR EXHAUST GAS RECIRCULATION VALVE

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 6 YEARS UNTIL 31 JAN 2023 BY AJ PARK

Effective date: 20201210

ASS Change of ownership

Owner name: TAKEDA PHARMACEUTICAL COMPANY, JP

Effective date: 20210621

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 31 JAN 2024 BY ANAQUA SERVICES

Effective date: 20221220

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 31 JAN 2025 BY ANAQUA SERVICES

Effective date: 20231220